CiteULike
Facebook
Mendeley
Twitter
This article is- freely available
- re-usable
Viruses 2010, 2(7), 1347-1366; doi:10.3390/v2071347
Review
Resistance to Integrase Inhibitors
Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
* Author to whom correspondence should be addressed.
Received: 27 April 2010; in revised form: 17 June 2010 / Accepted: 19 June 2010 / Published: 25 June 2010
(This article belongs to the Special Issue HIV Drug Resistance)
Download PDF Full-Text [1107 KB, Updated Version, uploaded 28 June 2010 15:47 CEST]
The original version is still available [583 KB, uploaded 25 June 2010 16:59 CEST]
Abstract: Integrase (IN) is a clinically validated target for the treatment of human immunodeficiency virus infections and raltegravir exhibits remarkable clinical activity. The next most advanced IN inhibitor is elvitegravir. However, mutant viruses lead to treatment failure and mutations within the IN coding sequence appear to confer cross-resistance. The characterization of those mutations is critical for the development of second generation IN inhibitors to overcome resistance. This review focuses on IN resistance based on structural and biochemical data, and on the role of the IN flexible loop i.e., between residues G140-G149 in drug action and resistance.
Keywords: AIDS; HIV-1 integrase; Raltegravir; Elvitegravir; GSK-1349572; GSK-1265744; interfacial inhibitors; resistance
Article Statistics
Click here to load and display the download statistics.Cite This Article
MDPI and ACS Style
Métifiot, M.; Marchand, C.; Maddali, K.; Pommier, Y. Resistance to Integrase Inhibitors. Viruses 2010, 2, 1347-1366.
AMA StyleMétifiot M, Marchand C, Maddali K, Pommier Y. Resistance to Integrase Inhibitors. Viruses. 2010; 2(7):1347-1366.
Chicago/Turabian StyleMétifiot, Mathieu; Marchand, Christophe; Maddali, Kasthuraiah; Pommier, Yves. 2010. "Resistance to Integrase Inhibitors." Viruses 2, no. 7: 1347-1366.